{"id":"NCT03941964","sponsor":"AbbVie","briefTitle":"A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","officialTitle":"A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-15","primaryCompletion":"2022-03-14","completion":"2022-03-14","firstPosted":"2019-05-08","resultsPosted":"2023-03-20","lastUpdate":"2023-03-20"},"enrollment":60,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia (AML)","Cancer"],"interventions":[{"type":"DRUG","name":"Venetoclax","otherNames":["ABT-199","VENCLEXTA","VENCLYXTO"]},{"type":"DRUG","name":"Azacitidine","otherNames":["Vidaza"]},{"type":"DRUG","name":"Decitabine","otherNames":["Dacogen"]}],"arms":[{"label":"Venetoclax 400 mg + azacitidine 75 mg","type":"EXPERIMENTAL"},{"label":"Venetoclax 400 mg + decitabine 20 mg","type":"EXPERIMENTAL"}],"summary":"A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-na√Øve participants with AML who are ineligible for intensive chemotherapy.","primaryOutcome":{"measure":"Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)","timeFrame":"Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.","effectByArm":[{"arm":"Venetoclax 400 mg + Azacitidine 75 mg","deltaMin":70,"sd":null},{"arm":"Venetoclax 400 mg + Decitabine 20 mg","deltaMin":63.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["38711253"],"seeAlso":["http://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":30},"commonTop":["ANAEMIA","NEUTROPHIL COUNT DECREASED","NAUSEA","WHITE BLOOD CELL COUNT DECREASED","PLATELET COUNT DECREASED"]}}